Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer-Reference-Cited by-同舟云学术

Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer

Published:2018-10-24 Issue: Volume: Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Chen Wanyuan¹,Fan Weimin²,Ru Guoqing¹,Huang Fang¹,Lu Xiaming¹,Zhang Xin¹,Mou Xiaozhou³,Wang Shibing³

Affiliation:

1. Department of Pathology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China

2. The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China

3. Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress in combination therapy of oncolytic vaccinia virus;Frontiers in Immunology;2024-03-13

2. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review;Cancer Biology & Medicine;2023-08-23

3. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy;Frontiers in Immunology;2023-01-10

4. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements;Frontiers in Immunology;2022-08-25

5. Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer;Molecular Therapy - Oncolytics;2022-06